Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors
Sign Up to like & getrecommendations! Published in 2022 at "Oncology"
DOI: 10.1159/000519605
Abstract: Background: The 2 approved somatostatin analogs (SSAs) in the first-line treatment of advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are octreotide long-acting release (Sandostatin LAR) and somatuline depot (Lanreotide). The study’s objective was to compare progression-free… read more here.
Keywords: octreotide lar; pfs; somatuline depot; treatment ... See more keywords